Dr Victoria Ann Brown, MD | |
30 N 4th St, 2nd Floor, Lebanon, PA 17046-5606 | |
(717) 274-0474 | |
(717) 274-0673 |
Full Name | Dr Victoria Ann Brown |
---|---|
Gender | Female |
Speciality | |
Experience | Years |
Location | 30 N 4th St, Lebanon, Pennsylvania |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1275565079 | NPI | - | NPPES |
001207802 | Medicaid | PA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | MD045500E (Pennsylvania) | Primary |
207VG0400X | Obstetrics & Gynecology - Gynecology | MD045500E (Pennsylvania) | Secondary |
Mailing Address | Practice Location Address |
---|---|
Dr Victoria Ann Brown, MD Po Box 300, Lebanon, PA 17042-0300 Ph: (717) 270-7780 | Dr Victoria Ann Brown, MD 30 N 4th St, 2nd Floor, Lebanon, PA 17046-5606 Ph: (717) 274-0474 |
News Archive
Benitec Biopharma, a biopharmaceutical company focused on providing potentially curative therapies with its proprietary gene-silencing technology called ddRNAi or "expressed RNAi," is pleased to advise that the fifth patient in the company's 'first in man', Phase I/IIa dose escalation clinical trial of TT-034 for hepatitis C virus (HCV) infection, has today, been dosed at the Duke Clinical Research Unit.
Tarsa Therapeutics, Inc. today announced that it has secured a $10 million senior credit facility from Oxford Finance LLC and Square 1 Bank. The company intends to use the proceeds to support its plans to file a New Drug Application (NDA) with the U.S. Food and Drug Administration for its Ostora tablet for the treatment of postmenopausal osteoporosis, currently targeted for early 2015.
More than 75 percent of fourth-graders in urban and rural settings have measurable levels of a nicotine breakdown product in their saliva that documents their second-hand smoke exposure, researchers report.
GlaxoSmithKline and XenoPort, Inc. announced today that GSK has resubmitted the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) requesting approval of Solzira(TM) (gabapentin enacarbil) Extended Release Tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).
High salt intake is associated with significantly greater risk of both stroke and cardiovascular disease, concludes a study published on bmj.com today.
› Verified 1 days ago
Dr. Gabrielle Frenkel, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 30 N 4th St, Lebanon, PA 17046 Phone: 717-274-0474 | |
Mrs. Heather Heck, CRNP Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1701 Cornwal Road, Lebanon, PA 17042 Phone: 717-675-1780 | |
Anthony Lal, Family Medicine Medicare: Medicare Enrolled Practice Location: 30 N 4th St, Lebanon, PA 17046 Phone: 717-274-0474 | |
Ilham Ahmed Umar, Family Medicine Medicare: Medicare Enrolled Practice Location: 30 N 4th St, Lebanon, PA 17046 Phone: 717-274-0474 | |
Robert Greville Brummett, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 855 Tuck St, Suite 1, Lebanon, PA 17042 Phone: 717-273-5395 | |
Wray Anthony Gerard, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 4th & Walnut St, Good Samaritan Hospital, Lebanon, PA 17042 Phone: 717-270-7740 Fax: 717-270-3877 | |
Dr. James D Stauffer, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 1700 S Lincoln Ave, Lebanon, PA 17042 Phone: 717-272-6621 Fax: 717-228-6002 |